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USP Apparatus 3 (reciprocating cylinder) is a very versatile device for the in vitro assessment of release 
characteristics of solid oral dosage forms, because it enables the product to be subjected to different 
dissolution media and agitation speeds in a single run. In this paper, a brief history and a description of this 
system are presented, along with its applications in the development of immediate and modified release 
products and in the simulation of fasted and fed states using biorelevant media. Furthermore, a comparison 
is made with the basket and paddle apparatus, especially highlighting the superior hydrodynamics of 
USP apparatus 3, since the results are not sensitive to factors such as the presence of sample collection 
probes or air bubbles in the dissolution medium.
Uniterms: Solid dosage forms/in vitro release. Solid dosage forms/dissolution. Apparatus 3/use/evaluation 
of solid dosage forms. Reciprocating cylinders.
USP aparato 3 (cilindros recíprocos) é um equipamento bastante versátil para a avaliação das 
características de liberação in vitro de formas farmacêuticas sólidas orais, pois permite que o produto seja 
submetido a diferentes meios de dissolução e condições de agitação, em um único ensaio. Neste trabalho, 
são apresentados um breve histórico e a descrição desse sistema, suas aplicações no desenvolvimento 
de produtos de liberação imediata e modificada, assim como sua utilização na simulação dos estados 
não alimentado e alimentado com o emprego de meios biorrelevantes. Além disso, uma comparação é 
estabelecida com o cesto e a pá, com destaque para a hidrodinâmica superior do USP aparato 3, que faz 
com que os resultados não sejam influenciados por fatores como o uso de sondas de coleta de amostras 
ou presença de bolhas de ar no meio de dissolução.
Unitermos: Formas farmacêuticas sólidas/liberação in vitro. Formas farmacêuticas sólidas/dissolução. 
USP Aparato 3/uso/avaliação de formas farmacêuticas sólidas. Cilindros recíprocos.
INTRODUCTION
Bioavailability and, consequently, the therapeutic 
effects of orally-administered medicinal products 
depend on the dissolution of the active ingredient 
in gastrointestinal fluids, as well as its permeation 
through the membrane of the luminal mucosa. Where 
the absorption process is rapid, dissolution may be the 
stage that controls the introduction of the drug into the 
bloodstream (Amidon et al., 1995; Emami, 2006). This, in 
turn, led to universal recognition that the dissolution test is 
indispensable in the development, quality assurance and 
post-marketing authorization modifications of solid oral 
dosage forms (Dokoumetzidis, Macheras, 2006; Azarmi, 
Roa, Löbenberg, 2007).
Furthermore, in the context of the Biopharmaceutics 
Classification System (BCS), proposed by Amidon et al. 
(1995), the dissolution test, together with bioavailability 
studies, has become an essential tool for the establishment 
of an in vitro-in vivo correlation (IVIVC) (FDA, 2000).
With regards to the apparatuses used in the 
dissolution test, the basket apparatus (USP apparatus 1) 
was the first to be adopted by the U.S. Pharmacopeia in 
1970, while the paddle apparatus (USP apparatus 2) was 
recognized in 1978, as the result of ongoing developments 
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in the area and a growing interest in matters related to 
dissolution (Dokoumetzidis, Macheras, 2006).
However, research in the field of modified release 
dosage forms has indicated that, in order to obtain a 
correlation between in vitro dissolution results and 
the bioavailability of these products (in vitro-in vivo 
correlation), it would be essential for the pH, composition, 
ionic strength, viscosity and agitation speed of the 
medium to be sequentially altered during the dissolution 
test, thus simulating passage of the product through the 
gastrointestinal tract. With the purpose of addressing 
this issue, a group of researchers from the University of 
London, headed by Professor A.H. Beckett, developed 
the reciprocating cylinder method (Borst, Ugwu, Beckett, 
1997; Yu, Wang, Hussain, 2002).
In the 1970s, Professor Beckett’s team used the 
rotating bottle method in order to assess the dissolution 
profiles of extended-release products, which presented 
important advantages over the basket and paddle 
apparatuses, especially with regards to hydrodynamics 
and the possibility of using the pH gradient. However, 
the method was extremely labor-intensive and there were 
limitations with regards to automatization of the system 
(Borst, Ugwu, Beckett, 1997; Jorgensen, Bhagwat, 1998).
Thus, the reciprocating cylinder apparatus was 
conceived, with a design based on the capsule and tablet 
disintegration device, associating the hydrodynamics of 
the rotating bottle method with the facility for exposing the 
dosage form to different dissolution media and agitation 
speeds, in a device that could be automated. This proposal 
was incorporated into the U.S. Pharmacopeia in 1991 (Yu, 
Wang, Hussain, 2002) as USP apparatus 3, making it an 
alternative to USP apparatuses 1 and 2 for the assessment 
of dissolution characteristics of products that consist of 
solid oral modified-release dosage forms (Borst, Ugwu, 
Beckett, 1997; Krämer, Grady, Gajendran, 2005; Wang, 
Fotaki, Mao, 2009).
Accordingly, considering the importance of 
assessing the dissolution of solid oral modified-release 
dosage forms with the reciprocating cylinder, the 
purpose of this study is to discuss the applications of this 
apparatus on the assessment of in vitro release of solid 
oral dosage forms and to establish a comparison between 
the aforementioned system and the basket and paddle 
apparatuses.
DESCRIPTION OF RECIPROCATING CYLIN-
DER APPARATUS
The main components of the reciprocating cylinder 
apparatus are internal cylinders, external cylinders, 
metallic agitation rods and the heating bath. Each unit 
of the dosage form is inserted into an internal cylinder, 
consisting of a glass tube closed at both ends with plastic 
caps containing a screen, which is made of nylon or 
stainless steel (Figure 1a). 
The internal cylinders are coupled to metallic rods 
that undertake the immersion and emersion movements 
(reciprocating action) within the dissolution vessel, which 
is called the external cylinder. This vessel is very different 
from the one used for the basket and paddle methods 
because, besides its distinctive cylindrical format and 
flat bottoms, it has a capacity of only 300 mL. Besides 
the standard 300 mL vessels, other vessels for specific 
applications are also available, with 100 mL and 1,000 mL 
capacities. An anti-evaporation system is deployed over 
the vessels in order to avoid alterations in the volumes of 
the dissolution medium during the assay, as illustrated in 
Figure 1b.
The heating bath contains dissolution vessels 
arranged in lines; temperature of the medium is maintained 
at 37 ºC. Each horizontal line consists of 7 vessels, 6 for 
the product and the seventh may be used for the standard 
solution, in systems in which the quantification stage is 
automated, or even to contain the replacement medium, in 
the event that this procedure is adopted after the collection 
of samples.
The internal cylinders remain in each line of 
vessels, in reciprocal movement, for pre-programmed 
times and intensities (dips per minute or “dpm”) in the 
FIGURE 1 – Reciprocating cylinder apparatus: (a) Internal 
cylinder and its top and bottom caps (b) illustration of the 
internal cylinder coupled to the rod inside the external cylinder 
(vessel).
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apparatus. During emersion, the agitation system rises 
until the screen in the lower cover touches the dosage 
form, which separates from the screen and floats freely in 
the dissolution medium when the stirring system activates. 
After the programmed period, the rods rise until the 
internal cylinders are positioned over the vessels, where 
they remain for a pre-established timeframe so that the 
dissolution medium can drain. Then the rods move to the 
following line, submerging again and the reciprocating 
actions begin anew.
The system contains six lines of vessels, but if a 
larger volume of dissolution medium is necessary to 
ensure sink conditions, it may be programmed so that, after 
the cylinders move along the sixth line, they return to the 
first, where the medium must be replaced.
The time the internal cylinders remain in each line of 
vessels as well as the pH, the composition, ionic strength 
and agitation speed of the dissolution medium may be 
selected, according to physiological conditions and, 
accordingly, it is possible to simulate the passage of the 
product through the gastrointestinal (GI) tract.
Samples are collected throughout the test in order 
to quantify the drug released and the dissolution profiles 
are traced after calculating the cumulative percentage of 
drug dissolved. Thus, the amount of drug released from 
the dosage form at the end of the test will correspond to the 
sum of percentages quantified in all the vessels covered.
APPLICATIONS FOR MODIFIED-RELEASE SOLID 
ORAL DOSAGE FORMS
Modified-release dosage forms offer therapeutic 
advantages over conventional release mechanisms due 
to the use of advanced technologies and excipients with 
special characteristics, and they are thus capable of 
generating a specific dissolution profile. However, the 
complexity that they present and the necessity for in vivo 
performance to be predictable and reproducible means 
development becomes more complex (Kumar, Domb, 
2004).
One issue to be considered is the time that these 
products remain in the GI tract, which is greater compared 
to the immediate-release forms, since the latter undergo 
rapid disaggregation when they come in contact with an 
aqueous medium. As a result of the greater exposure time, 
the performance of extended-release products is more 
susceptible to the mechanical forces and physicochemical 
conditions of the luminal environment (Dokoumetzidis, 
Macheras, 2006). Since the reciprocating cylinder method 
enables these conditions to be simulated, it is reasonable 
to suppose that this apparatus is more efficient than the 
basket and paddle methods in predicting the in vivo 
performance of extended-release dosage forms (Krämer, 
Grady, Gajendran, 2005; Pezzini, Ferraz, 2009).
One fundamental condition for the development 
of dissolution methodologies is the suitable selection of 
the pH of the medium, since this affects drug solubility. 
These methodologies involve mostly weak acids or bases 
(Klein et al., 2005). When modified-release products are 
tested in apparatus 3, it is possible to simulate the different 
environments to which the dosage forms are subject when 
they pass through the GI tract (Figure 2). These conditions 
can be assessed by employing different buffer solutions 
with or without surfactants (Pezzini, Ferraz, 2009; Ribeiro, 
Ferreira, Veiga, 2005).
Figures 3 and 4 present hypothetical dissolution 
profile of an extended-release formulation in USP 
apparatuses 1 and 3, respectively.
In the hypothetical cases listed early, it can be 
observed that the formulation releases the drug in a similar 
fashion to USP apparatuses 1 (pH 6.8) and 3 (pH gradient). 
However, with the results obtained in USP apparatus 3, it 
is possible to assess that the product should not present 
any dose-dumping issues, since, under all pH conditions, 
no drug delivery peaks are registered, which indicates that 
the formulation is capable of resisting the pH gradient to 
which it will be subjected during its passage through the 
GI tract. This information is of great use to the formulator.
USP Apparatus 3 also has an important application 
in the assessment of gastro-resistant formulations, 
considering the possibility of change in the dissolution 
FIGURE 2 - Schematic representation of apparatus 3 and its six 
lines of vessels, each containing a dissolution medium with a 
different pH value, by way of example, simulating the passage 
of the product through the gastrointestinal (GI) tract (Borst, 
Ugwu, Beckett, 1997).
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medium during the assay. The dissolution profiles of 
a hypothetical gastro-resistant formulation in USP 
apparatuses 1 and 3 can be found in Figures 5 and 6, 
respectively.
From the observation of the hypothetical dissolution 
profiles in the figures above, it is possible to state that 
the use of USP apparatus 3 in the development of colon-
targeted and enteric-release dosage forms is especially 
significant (Yang, 2008). In the conditions of USP 
apparatus 1 (Figure 5), it is not possible to assess the 
capacity of the formulation to resist the acid medium of 
the stomach. However, considering USP apparatus 3, 
it is perfectly feasible to execute a much more detailed 
description of the drug delivery in this type of formulation, 
thus establishing the pH in which the dissolution actually 
takes place.
SIMULATION OF FASTED AND FED STATES
Besides its use in the development of dosage 
forms, the dissolution test has become an important 
tool in assessing the performance of formulations 
under conditions very close to those encountered in the 
human gastrointestinal (GI) tract. However, in order to 
achieve this, the assays must be outlined and executed 
in conditions different from those usually employed 
FIGURE 4 - Dissolution profile representing a hypothetical 
extended-release formulation using apparatus 3 under different 
pH conditions (1.2, 4.5, 6.8, 7.2 and 7.5).
FIGURE 5 - Hypothetical dissolution profile of a gastro-resistant 
formulation using USP apparatus 1 in a pH 6.8 buffer.
FIGURE 6 - Hypothetical dissolution profile of a gastro-resistant 
formulation using USP apparatus 3 in three different media (pH 
1.2, 4.5 and 6.8).
FIGURE 3 - Dissolution profile representing a hypothetical 
extended-release formulation using USP apparatus 1 in a pH 
6.8 buffer solution.
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and described in Pharmacopoeias, both in terms of the 
equipment used and in the composition of dissolution 
media, such that they simulate the nutritional state of the 
patient (Klein, 2010).
Accordingly, Dressman et al. (1998) suggest 
alterations to the composition of dissolution media so that 
they can correspond better to fasted and fed states. This is 
the beginning of the use of the so-called biorelevant media; 
i.e., dissolution media with compositions that are similar to 
the conditions encountered in the GI tract. Factors such as 
pH, buffer capacity, presence of surfactants and enzymes, 
volume of fluid present in the GI tract and hydrodynamics, 
must be taken into account when it comes to a biorelevant 
dissolution medium.
Thus, besides the use of biorelevant media, the 
simulation of the fasted and fed states requires the use of 
conditions that reflect the hydrodynamics of the GI tract 
as closely as possible. Accordingly, the reciprocating 
cylinder apparatus is beneficial for this type of assessment. 
If simulation of the fed state is desired, agitation of the 
product may be executed for 1 hour in the first line of 
vessels. In order to mimic the fasted state, this time may 
be increased to 4 hours, followed by 1 hour of agitation 
in the second line. In both cases, the appropriate agitation 
period in other lines must be selected depending on the 
type of product to be analyzed, compared to the drug 
delivery time, which may be from 8 to 24 hours (Yang, 
2008; Asare-Addo et al., 2011).
Another important issue involves the mechanical 
forces and the degree of agitation to which the product is 
exposed in the GI tract, in the form of intestinal motility 
and pressure on the stomach, duodenum and jejunum. 
It is particularly critical in the case of dosage forms 
that are subject to erosion, such as hydrophilic matrices 
(Kavanagh, Corrigan, 2004; Missaghi, Fassihi, 2005; 
Asare-Addo et al., 2010). Although it may be difficult 
to select the agitation intensity that best mimics in vivo 
conditions, it is common to use 5-15 dips per minute 
(dpm) to simulate the fasted state and 30-40 dpm for the 
fed state, thus representing the greater turbulence within 
the stomach (Borst, Ugwu, Beckett, 1997). Furthermore, 
inert spheres of varying densities may be added in order to 
simulate interaction with solid food particles in movement 
(Missaghi, Fassihi, 2005).
With regards to the composition of the dissolution 
media, several approaches may be used to simulate the 
presence of foodstuffs in the GI tract. One example is 
immersion of the dosage form in peanut oil, and stirring 
it for 2 hours at 37 °C and then begin the assay using 
dissolution media that reflect the different pH values and 
ionic strength present in the GI tract in the fasted state. 
Another possibility would be to eliminate prior treatment 
of the sample and then add peanut oil to the dissolution 
medium of the first lines of vessels. The other conditions 
for undertaking the test are similar to these described 
previously (Mu, Tobyn, Staniforth, 2003).
Besides these approaches, biorelevant dissolution 
media constitute a very interesting tool, because they are 
more capable of simulating drug delivery throughout the 
GI tract, in both the fasted and fed state, and they are now 
used very frequently (Wang, Fotaki, Mao, 2009; Jantratid, 
Dressman, 2009).
Besides pH and volume, these types of dissolution 
media take into account other characteristics such as 
osmotic concentration, the presence of enzymes and 
surface tension, as a means of best mimicking especially 
the conditions in the small intestine, including the presence 
of bile salts (Witzleb et al., 2012; Zoeller, Dressman, 
Klein, 2012).
APPLICATIONS OF USP APPARATUS 3 FOR 
IMMEDIATE-RELEASE DOSAGE FORMS
Although it has been conceived for dissolution 
tests involving extended-release dosage forms, the 
reciprocating cylinder apparatus has a significant potential 
for assessing immediate-release dosage forms.
One advantage of its use in this case is the 
significantly reduced quantity of water and reagents 
required for the preparation of the media, considering the 
volume of the dissolution vessels, compared to the basket 
and paddle methods (Yu, Wang, Hussain, 2002).
However, a smaller medium volume may make the 
equipment unfeasible for products containing poorly-
soluble drugs, unless measures are taken to ensure sink 
conditions. Examples of possibilities are the use of larger 
vessels, up to 1,000 mL and the addition of surfactants to 
the dissolution medium (Yu, Wang, Hussain, 2002). In this 
latter case, the use of an anti-foam agent may be necessary, 
since the movement of the cylinders may generate a large 
amount of foam (Jorgensen, Bhagwat, 1998).
It is important to emphasize that, contrary to 
modified-release dosage forms, the use of several lines 
of vessels containing the dissolution medium may not be 
applied to immediate-release products. This is because 
the dosage form disintegrates; generating fragments that 
may come out of the internal cylinder and pass through 
the screen of the lower cover. The drug present in these 
fragments may still be encountered in its undissolved 
state when the last samples are collected, which occurs 
shortly before the metallic rods move the internal 
cylinders to the next line of vessels. Accordingly, results 
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will be compromised due to the loss of undissolved drug 
throughout the test.
USP Apparatus 3 also may be used as for chewable 
tablets, with the use of glass spheres during the test in 
order to increase the agitation speed (Siewert et al., 2003).
ADVANTAGES OVER TRADITIONAL ME-
THODS
The basket and paddle apparatus are well established 
and broadly used for the assessment of in vitro dissolution 
of solid oral dosage forms. Despite the great popularity of 
these methods, they present some disadvantages (Hanson; 
Gray, 2004).
With regards to USP apparatus 1, the results obtained 
may suffer interference and obstruction of the basket 
screen, which may occur during the assessment of matrix 
formulations that are subject to swelling. Furthermore, 
drug particles may be expelled and float to the surface 
of the dissolution medium (lower density) or settle at 
the bottom of the vessel (higher density) (Borst, Ugwu, 
Beckett, 1997; Jorgensen, Bhagwat, 1998).
With regards to USP apparatus 2, the phenomenon 
called coning may be observed. It is characterized by the 
formation of a cone of powder/granules at the bottom of 
the vessel when the medium is being stirred, due to the 
poor agitation capacity of the system, especially when it is 
operated at 50 rpm. The particles in the cone are subjected 
to a lower agitation speed, which may reduce dissolution 
and affect the variability of the results (Borst, Ugwu, 
Beckett, 1997; Yu, Wang, Hussain, 2002; Krämer, Grady, 
Gajendran, 2005). 
Due to the design and reciprocal action of USP 
apparatus 3, none of the aforementioned problems have 
been observed. Furthermore, the results are not influenced 
by the presence of bubbles in the dissolution medium, 
making degasification of the medium unnecessary, thus 
representing huge time savings and greater practicality. 
Accordingly, the system is considered to have superior 
hydrodynamics compared to the basket and paddle 
apparatus (Borst, Ugwu, Beckett, 1997; Jorgensen, 
Bhagwat, 1998).
Another significant advantage of the reciprocating 
cylinder apparatus is the consumption of dissolution 
media, since tests can be conducted using a volume of 
up to 300 mL. Furthermore, the minimum operational 
volume for this apparatus is around 150 mL. This is an 
advantage compared to USP apparatuses 1 and 2, when 
it comes to their use in the dissolution of products that 
require a smaller volume of dissolution medium (Cryst, 
2009).
Furthermore, the reciprocating cylinder apparatus 
enables a better assessment of the dosage form under 
different pH conditions during the test. This type of 
evaluation, when executed in USP apparatuses 1 or 2, 
requires a change in the dissolution medium that is difficult 
to conduct. Accordingly, USP apparatus 3 may be used for 
a more faithful assessment of release mechanisms under 
physiological conditions (Brown, 2005).
USP apparatus 3 can be used to evaluate drug release 
from hydroxypropylmethyl cellulose (HPMC) extended-
release tablets. Considering that erosion is the dominant 
release mechanism from HPMC tablets containing poorly-
soluble drugs and that the presence of food components 
in gastrointestinal tract have a critical effect on tablet 
disintegration, different dip rates from this apparatus in 
the evaluation of these dosage forms could be related to 
food effects on HPMC erosion (Asare-Addo et al., 2010).
FINAL CONSIDERATIONS
USP apparatus 3 has important advantages over 
the basket and paddle apparatuses in the assessment of 
in vitro dissolution characteristics of modified-release 
dosage forms. As the apparatus is very versatile, its 
application is not restricted to extended-release products, 
and it may also be used for other solid oral dosage forms, 
such as immediate-release forms, and it is a useful tool in 
the simulation of fasted and fed states, using biorelevant 
media.
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